The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15663130.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The levonorgestrel-releasing intrauterine system (LNG-IUS) is used commonly by gynaecologists as a contraceptive and to treat menorrhagia. However, its efficacy has not been examined in women with inherited bleeding disorders. A prospective pilot study. A teaching hospital in north London with a designated haemophilia centre. Female patients with a known inherited bleeding disorder. Sixteen women with subjective and objective menorrhagia caused by inherited bleeding disorders (13 von Willebrand's Disease, two factor XI deficiency and one Hermansky-Pudlak syndrome), who had previously undergone unsuccessful medical treatment were followed up for nine months after LNG-IUS insertion. Bleeding was measured by pictorial chart and haemoglobin concentration. All women reported that their periods were improved, pictorial chart scores were lower and 56% became amenorrhoeic. None reported side effects. The LNG-IUS is well tolerated and effective and improves quality of life.
Medical subject headings
- Blood Coagulation Disorders, Inherited
- Contraceptive Agents, Female
- Intrauterine Devices, Medicated
- Levonorgestrel
- Menorrhagia